Colchicine as an oral corticosteroid sparing agent for asthma

秋水仙碱作为一种口服皮质类固醇替代药物用于治疗哮喘

阅读:1

Abstract

BACKGROUND: Oral corticosteroids are used as a treatment for asthma, but they are often associated with serious side effects. Colchicine is an anti-inflammatory, immuno modulating agent, which could potentially have a beneficial effect in the treatment of asthma as well as act as a steroid-sparing agent. OBJECTIVES: To determine the effectiveness of colchicine as an oral corticosteroid sparing agent for in the treatment of chronic asthma. SEARCH STRATEGY: We searched the Cochrane Airways Group trials register (November 2002), SIGLE (1980 to 2001) and reference lists of potential articles. We also contacted researchers in the field. SELECTION CRITERIA: Randomised controlled trials investigating the addition of colchicine compared to placebo in stable steroid dependent asthmatics. DATA COLLECTION AND ANALYSIS: No trials were found that met the inclusion criteria. MAIN RESULTS: We were unable to perform any meta-analyses. Two small studies have assessed the efficacy of colchicine subsequent to inhaled steroid withdrawal and as a tapering agent in inhaled steroids. Both studies failed to detect a significant difference between colchicine and placebo. REVIEWER'S CONCLUSIONS: No relevant trials have been published, so there is no evidence to indicate that colchicine is beneficial or otherwise in the management of steroid-dependent asthmatic patients. There is a need for well designed randomised controlled trials to be performed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。